Back to mobile site
Get it on Google Play

FDA approves Atebrioz for rare bone-forming disease in patients 12 and up

September 25, 2026 7:00 PM EDT Send to a Friend
Mirum Pharmaceuticals (NASDAQ: MIRM) and Incyte (NASDAQ: INCY) announced that the U.S. Food and Drug Administration has approved Atebrioz (zilurgisertib) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login